×
Aptorum Group EBIT 2018-2024 | APM
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Aptorum Group ebit from 2018 to 2024. Ebit can be defined as earnings before interest and taxes.
View More
Aptorum Group EBIT 2018-2024 | APM
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Aptorum Group ebit from 2018 to 2024. Ebit can be defined as earnings before interest and taxes.
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$75.9B
Zoetis (ZTS)
$67.3B
Takeda Pharmaceutical (TAK)
$46.3B
Daiichi Sankyo, - (DSNKY)
$45.5B
BeOne Medicines - (ONC)
$32.4B
Sandoz Group AG (SDZNY)
$25.8B
Summit Therapeutics (SMMT)
$19.7B
Merck (MKKGY)
$16.7B
Shionogi (SGIOY)
$14B
United Therapeutics (UTHR)
$13.4B
Neurocrine Biosciences (NBIX)
$13.1B
Orion OYJ (ORINY)
$11.7B
IPSEN (IPSEY)
$10.3B
Stevanato Group S.p.A (STVN)
$7.4B
Corcept Therapeutics (CORT)
$7.3B
Madrigal Pharmaceuticals (MDGL)
$7B
Ionis Pharmaceuticals (IONS)
$6.7B
Grifols, S.A (GRFS)
$6.6B
Hikma Pharmaceuticals Plc (HKMPF)
$6.2B
Ono Pharmaceutical (OPHLF)
$5.2B
Soleno Therapeutics (SLNO)
$4.3B
Procaps Group, S.A (PROCF)
$3.2B
Hypermarcas (HYPMY)
$3B
Crinetics Pharmaceuticals (CRNX)
$2.9B
NewAmsterdam Pharma (NAMS)
$2.6B
Catalyst Pharmaceuticals (CPRX)
$2.5B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.5B
Centessa Pharmaceuticals (CNTA)
$2.2B
Ocular Therapeutix (OCUL)
$1.8B
BioCryst Pharmaceuticals (BCRX)
$1.8B